T3 Live

The Bull Case for Viking Therapeutics


David Prince has been a long-term bull on Viking Therapeutics (VKNG) for some time as a prime play in the weight loss drug space, which has been dominated by Eli Lilly (LLY) and Novo Nordisk (NVO).

In this video from May 1, David explains why the company might be taken over in the future by a larger company like Pfizer (PFE), Merck (MRK), or Bristol-Myers (BMY)

Leave a Comment: